{"id":"fibromyalgia-genetics-pain-science-16518","slug":"fibromyalgia-genetics-pain-science-16518","title":"Fibromyalgia's 26 Genetic Clues","description":"Fibromyalgia affects millions, yet it was long dismissed as a diagnosis of exclusion. A July genetic study of 2.5 million people identified 26 associated genome regions and pointed squarely at the central nervous system, while a major drug review this month delivered far less encouraging news. This episode explores what nociplastic pain actually means, why the HTT gene link surprised researchers, and how much of the condition remains unexplained.","excerpt":"A landmark study found 26 genetic regions linked to fibromyalgia — but the drugs are still catching up.","pubDate":"2026-10-23T18:04:07.365Z","tags":["healthcare-systems","medieval-world","stress-and-trauma","sensory-processing","public-health"],"heroImage":"https://files.myweirdprompts.com/covers/fibromyalgia-genetics-pain-science-16518.png","podcastAudioUrl":"https://episodes.myweirdprompts.com/audio/fibromyalgia-genetics-pain-science-16518.m4a","podcastDuration":"23:55","episodeNumber":6233,"transcript":"Corn: Twenty-six genetic risk regions, and still no blood test that tells you whether you have it. That's the peculiar position fibromyalgia occupies now. Daniel, your route into this started with the stomach bug and cold currently flattening the household.\n\nDaniel: Hannah, Ezra and I have been getting these bugs repeatedly, and thinking about why infections cause stomach aches somehow brought me to fibromyalgia. I know very little about it. I remember it being dismissed much like chronic fatigue syndrome. Has the science actually settled anything?\n\nHerman: Quite a lot about biological susceptibility, much less about how to relieve it. Those have moved at painfully different speeds. The biggest genetic study arrived in July, and a major review of medicines arrived this month. Reading them together gives you both genuine progress and a fairly sharp disappointment.\n\nCorn: The laboratory has overtaken the prescription pad.\n\nDaniel: When people say fibromyalgia, what are they actually describing? Is it aching muscles, or something broader?\n\nHerman: Persistent widespread pain, usually accompanied by fatigue, unrefreshing sleep and cognitive difficulties. People call that last part brain fog. Headaches and depression can accompany it, too. The pain matters, but so does waking after a night's sleep feeling as though the night never happened.\n\nCorn: Sleep without the service provided.\n\nHerman: Corn has strong contractual expectations of sleep. In this case they're justified. Someone can have enough hours in bed and still have severely disrupted restorative sleep. That interacts with pain and concentration, so treating the symptoms as unrelated complaints misses how they reinforce one another.\n\nCorn: You're explaining me as a clinical comparison again.\n\nHerman: Only your commitment to the subject.\n\nDaniel: Does the pain mean something is damaged? If someone says their whole body hurts, I'd assume inflammation or muscle injury.\n\nHerman: Sometimes those coexist, and clinicians still need to look for them. Fibromyalgia is usually described as nociplastic pain. Pain processing has changed without the tissue damage that would adequately explain the symptoms, and without a nerve lesion explaining them either.\n\nCorn: Those distinctions are useful. A cut produces nociceptive pain. A damaged nerve can produce neuropathic pain. Here the nervous system can produce an excessive pain response even though the examination doesn't reveal an injury proportionate to it.\n\nHerman: Central sensitisation is the dominant account. The central nervous system becomes unusually responsive to sensory input. Hyperalgesia means something painful hurts more than expected. Allodynia means something ordinarily non-painful, such as light contact, can hurt.\n\nDaniel: That sounds like a mechanism. Why isn't that already the cause?\n\nHerman: Because describing altered pain processing doesn't explain why that person's processing changed. Sleep, prior pain, inherited susceptibility and possibly immune activity can all enter the picture. Central sensitisation is useful, but it doesn't establish one complete chain of events for every patient.\n\nCorn: Herman, I predict you're about to enjoy the genetic machinery more than the uncertainty permits.\n\nHerman: I can enjoy machinery without claiming it explains the whole building.\n\nCorn: Your excitement has planning permission already.\n\nHerman: Here's the concrete advance. The July Nature Medicine analysis compared genetic variation across roughly two and a half million people, including about fifty-five thousand diagnosed cases. It identified twenty-six associated regions of the genome. That's a much stronger foundation than noticing a handful of candidate genes in small samples.\n\nDaniel: What does associated mean here? They found something patients had and other people didn't?\n\nHerman: More often, not exclusively. These are differences in how common variants are between groups. Each usually changes susceptibility modestly. The important next step was asking where the implicated biology operates. The inherited signal was enriched in brain tissues and neural cell types.\n\nCorn: The enrichment points toward the nervous system. It doesn't mean every symptom originates at one location in the brain, or that other organs have been cleared of involvement.\n\nHerman: The authors describe fibromyalgia as a central nervous system disorder. That directly challenges the old suggestion that these people simply lacked a genuine biological illness. Michael Wainberg, a senior author, called the biological basis “absolutely indisputable.”\n\nDaniel: Does that mean the argument is over?\n\nCorn: The argument that people need a visible injury before their pain counts should have ended earlier. This gives it substantially less room to hide. The argument about the exact biology is very much alive.\n\nHerman: Corn, would you consider it enough to retire “diagnosis of exclusion” as the whole description?\n\nCorn: You can identify a consistent symptom pattern rather than simply run out of alternatives. Still check for other illnesses. A fibromyalgia diagnosis doesn't prevent someone also having arthritis, thyroid disease or another cause of fatigue.\n\nHerman: That distinction matters clinically. “We recognise this pattern” and “we have stopped investigating anything” are different decisions.\n\nDaniel: What was the most surprising gene?\n\nHerman: HTT. The strongest association was a coding variant in the gene associated with Huntington's disease. Carriers had about nine percent higher odds of fibromyalgia. Small individual effect, striking biological clue.\n\nCorn: Before anyone hears that as a second diagnosis arriving...\n\nHerman: A different variant causes Huntington's disease. This finding does not mean fibromyalgia is Huntington's, or that a fibromyalgia diagnosis predicts it. Genes perform ordinary biological jobs as well as becoming associated with particular diseases.\n\nDaniel: Is there anything useful in that connection beyond the surprise?\n\nHerman: Potentially. Another implicated gene, GPR52, encodes a brain-specific receptor involved in regulating huntingtin levels. It's already of interest in Huntington's drug development. That creates a route worth investigating, not a medicine we can transfer straight into practice.\n\nCorn: A shared gene is not a transferable prescription.\n\nHerman: Other signals concern neural development, signalling and excitability. CELF4, for instance, helps regulate the excitability of pain-sensing neurons. I'm tempted to list the rest...\n\nCorn: Your face has become an appendix.\n\nHerman: I'll spare you the gene inventory. The collective pattern is more informative than any one name. There were also strong genetic correlations with low back pain, PTSD and irritable bowel syndrome, above point seven.\n\nDaniel: Does that mean the same genes cause all of those?\n\nHerman: It means inherited susceptibility overlaps substantially. It doesn't establish identical causes or make the conditions interchangeable. Shared pathways might eventually offer treatments across several conditions, but that's a development prospect.\n\nCorn: It also helps explain why a patient can collect diagnoses without collecting separate explanations. Pain, bowel symptoms and disturbed sleep may be interacting rather than coincidentally arriving together.\n\nHerman: We now go live to Monty, apparently reporting from a carnival in honour of today's topic.\n\nMonty: I am standing here in the middle of the Avenue of Central Sensitisation, where the samba band is so loud I can barely hear myself think, and the floats behind me are throwing glitter shaped like the letter H T T, which is either a genetic locus or a very confused tribute to Huntington, and I have been told to report on fibromyalgia but honestly the whole parade has been drowned out since the second bar.\n\nCorn: Monty, can you get somewhere quieter?\n\nMonty: The crowd is enormous, something like two and a half million people, and every single one of them is asking me whether the pain is in the brain or in the body, and I keep pointing at the giant inflatable neurone and shouting that it is both, it is always both, but the trombones will not let me finish.\n\nMonty: Monty, reporting live from the Carnival of Widespread Tenderness, where the samba has now been going for six hours and nobody has slept.\n\nHerman: Those overlapping genetic signals also complicate the idea that we should look for a single isolated defect. There may be multiple routes into the same clinical pattern.\n\nDaniel: Why do I mostly hear about women having it?\n\nHerman: Women are diagnosed roughly three times as often, but the genetic architecture was nearly identical across sexes. That points us toward other explanations for the difference, including hormones, environmental exposure, pain sensitivity and diagnostic habits.\n\nCorn: Hormones are biology too. We shouldn't translate “not explained by these inherited differences” into “not biological.”\n\nHerman: Fair correction. Not explained by a substantially different inherited architecture. The study also had an ancestry limitation, with about ninety percent of cases of European ancestry. A huge sample doesn't automatically represent everybody.\n\nDaniel: Can people get tested for the variants?\n\nHerman: They won't give a useful yes or no diagnosis. Plenty of people carry susceptibility variants without developing fibromyalgia. The authors suspect an additional trigger may matter, perhaps an existing painful arthritic condition. We haven't established one universal trigger.\n\nCorn: Twenty-six clues, no diagnostic barcode.\n\nDaniel: What about the idea that it's autoimmune?\n\nHerman: Still open. Patient-derived antibodies have produced pain hypersensitivity experimentally and bound cells around sensory nerve structures. That's intriguing. A trial removing antibodies from the blood reported only small group-level effects, though. The neurological genetic signal doesn't rule out immune contributions, and those antibody findings don't establish autoimmunity as everyone's explanation.\n\nCorn: The trouble historically was that uncertainty got treated as evidence against the patient. Fibromyalgia was recognised decades ago. Formal criteria in nineteen ninety relied heavily on tender points, places where pressure elicited pain. Later criteria incorporated fatigue, sleep and cognitive symptoms more directly.\n\nHerman: The generalised pain requirement added in twenty sixteen helped avoid classifying regional pain as fibromyalgia. Diagnosis evolved as clinicians recognised that pressing particular spots wasn't capturing the full condition.\n\nDaniel: Was the old diagnosis unreliable, then, or were doctors just dismissive?\n\nCorn: Both things can happen. Criteria can improve while patients were still telling the truth. A changing definition does not retroactively make their pain imaginary.\n\nHerman: That's the parallel with ME/CFS. People were discredited as witnesses to their own illness. An unfamiliar symptom pattern became a reason to doubt the person describing it, instead of a reason to improve the explanation.\n\nDaniel: How common is this? Are we talking about a rare condition with an unusually visible patient community?\n\nHerman: Estimates generally cluster around two to four percent worldwide. A large American survey put self-reported prevalence around two percent. The commonly quoted American count is about four million adults, possibly more, depending on definition and ascertainment.\n\nCorn: Those aren't interchangeable measurements. Survey reporting, diagnosed cases and symptom-based estimates capture different groups. You can make the condition look rarer simply by counting only people who managed to get diagnosed.\n\nHerman: Within the genetic study's contributing cohorts, recorded prevalence ranged from roughly one percent to more than seven percent. That reflects different populations and recording practices as well as potential differences in illness.\n\nDaniel: If the diagnosis is still clinical, what stops it becoming a label for anything doctors can't explain?\n\nHerman: A structured assessment of widespread pain and associated symptoms, their persistence and their distribution. Plus examination and targeted investigation where another condition is plausible. The new Royal College of Physicians guidance this month supports that process and explicitly recognises fluctuating symptoms.\n\nCorn: Diagnostic uncertainty calls for follow-up, not an unlimited licence to label everything fibromyalgia. Equally, normal routine blood results don't measure whether someone's pain processing is normal.\n\nHerman: Corn, suppose your pain improved but your fatigue didn't. Would you call a medicine successful?\n\nCorn: Partly successful. I'd care whether I could do something I'd stopped doing, and what the medicine cost me in side effects. If I slept longer but felt foggier all morning, a better sleep score wouldn't settle it.\n\nHerman: That's why the treatment review is so useful. It examined pain, sleep, overall symptoms and physical and mental health separately. “Better” can mean several things.\n\nDaniel: What drugs are actually available?\n\nHerman: Four have FDA approval for fibromyalgia. Pregabalin affects neural excitability. Duloxetine and milnacipran alter serotonin and noradrenaline signalling, including pathways involved in pain regulation.\n\nHerman: The newer addition is sublingual cyclobenzaprine, approved in August last year. Other medicines are used off label. The European Medicines Agency has approved none specifically for fibromyalgia, judging the evidence of benefit insufficient.\n\nCorn: The Atlantic is doing a lot of regulatory work.\n\nDaniel: That sounds like a major disagreement. Is Europe denying the condition exists?\n\nCorn: No. Doubting a drug's demonstrated benefit is entirely compatible with accepting the illness. Those judgments must stay separate, or every disappointing trial becomes another referendum on patients.\n\nHerman: The October BMJ Medicine review pooled a hundred and fifty-one randomised trials involving more than thirty-two thousand participants. It used a network analysis, allowing comparisons across treatments even when every pair hadn't been directly tested.\n\nDaniel: What did it find in plain language?\n\nHerman: Some medicines may help some people report meaningful improvement. Certain classes may help sleep or overall symptoms. The benefits were generally small and uncertain. No drug's pooled effect on pain, physical health or mental health reached the review's threshold for clinical importance.\n\nCorn: A very crowded medicine cabinet for that result.\n\nHerman: It doesn't mean no individual benefits. An average can conceal responders. It does mean we shouldn't promise that the typical patient will achieve a substantial improvement from the evidence available.\n\nDaniel: I'm struggling with “meaningful improvement” alongside “not clinically important.” Aren't those opposites?\n\nHerman: Different outcomes. Someone might answer a global question saying they're better because they sleep more comfortably or feel less distressed. Their measured pain reduction might remain small. Also, different analyses use different definitions of improvement. We shouldn't compress all of them into one success rate.\n\nCorn: Nor assume someone is wrong about feeling better because their pain score stayed steady. Being less exhausted matters. It just doesn't demonstrate a large pain-relieving effect.\n\nHerman: There's also a trial problem. Side effects can reveal who received the active medicine, weakening blinding. Expectations can then influence global ratings. That doesn't erase reported improvement, but it makes interpretation harder.\n\nDaniel: Were these long trials? People have this for years.\n\nHerman: The median follow-up was twelve weeks. Only nine trials reported results beyond six months. That leaves a large mismatch between the duration of the illness and the duration of most evidence.\n\nCorn: Chronic condition. Seasonal evidence.\n\nHerman: Roughly sixty percent were industry funded, and fifteen trials were flagged for trustworthiness concerns. Industry support doesn't automatically invalidate a result. Short follow-up, uncertain evidence and questionable trials collectively limit confidence.\n\nDaniel: What about cannabis or low-dose naltrexone? Those names come up around chronic pain.\n\nHerman: This review didn't establish benefit for either. They shouldn't be presented as the answer that conventional medicine somehow overlooked. They're investigated options with inadequate evidence here.\n\nCorn: Novelty can be remarkably good at impersonating effectiveness.\n\nHerman: Would you accept a small benefit, Corn, if there were almost no downside?\n\nCorn: My objection is to selling a small uncertain benefit as a transformation. I would also want to know whether it persisted. Twelve better weeks might matter enormously, but twelve weeks cannot tell me about the next several years.\n\nDaniel: If medicines are that limited, what does treatment actually consist of?\n\nHerman: Individually adapted aerobic activity and strengthening, physical therapy, support for sleep and psychological therapies, including CBT. Care usually involves several modest interventions rather than one decisive prescription. It can often be coordinated in primary care, though complicated cases need specialist input.\n\nCorn: CBT needs careful explanation in this context. After years of hearing “it's psychological,” being offered psychological therapy can sound like the same dismissal wearing a different tie.\n\nHerman: Its role is to help with the consequences and reinforcing processes of persistent pain, including disrupted activity, sleep and distress. Benefiting from it doesn't prove that faulty thinking caused the illness.\n\nDaniel: Does the exercise recommendation also apply to chronic fatigue syndrome?\n\nHerman: We need to separate them there. ME/CFS has post-exertional malaise as a central feature, a disproportionate worsening after exertion. Fibromyalgia and ME/CFS can overlap, but their criteria and management considerations differ. You cannot simply transfer an exercise prescription between them.\n\nCorn: Even within fibromyalgia, “exercise” doesn't mean ignore symptoms and push indefinitely. Adaptation is the substance of the recommendation, not a footnote.\n\nHerman: I nearly said exercise is the strongest treatment. More carefully, it's a cornerstone of care, not a guaranteed solution. Symptoms fluctuate, and building a sustainable level of activity can take time.\n\nDaniel: That fluctuation must make the disbelief worse. Someone sees you on a better day and assumes you've recovered.\n\nCorn: Patient advocate Kristal Kent describes seeming okay one day and being crashed out in a flare the next. A brief encounter gives an observer a very small sample. The observer often gives that sample extraordinary authority.\n\nHerman: The stakes are serious. An American survey analysis found almost sixfold higher odds of a past-year suicide attempt among people reporting fibromyalgia. That's an association, not proof of one cause. Pain, sleep disruption, depression and social consequences can compound each other.\n\nCorn: Someone can be suffering badly while looking entirely ordinary. A useful clinical conversation has to leave room for...\n\nHilbert: ...the woman who carried the committee downstairs. My cousin Vera had widespread pain before anyone gave it a useful name. Our Amateur Operetta Society met upstairs in nineteen eighty-five. Rule eleven said the secretary had to be physically present. They refused to move the meeting, so Vera carried the entire committee downstairs in the minutes. Eight names. “Removed by secretary.” That started the dispute.\n\nCorn: Moving the people on paper was considerably easier.\n\nHilbert: She wasn't attending. She was doing the telephone calls, collecting subscriptions and rearranging rehearsals from her kitchen. People kept saying she couldn't be very ill if the society still functioned. Herman, when you separated fatigue from sleep earlier, I thought of her afternoon calls. I'd always thought she disliked speaking after lunch.\n\nHerman: Keeping the administration running hid how much she had stopped doing elsewhere.\n\nHilbert: Her sister brought a doctor to dinner. He was courting her. He passed the beans and told Vera it was “just stress” and she should “try yoga.” I remember the beans because she couldn't lift the dish. I wanted a reclining chair for her. Priced one at a hundred and eighty-nine pounds. Didn't buy it. She said it would become the society's registered office.\n\nCorn: Under rule eleven, that seems a legitimate concern.\n\nHilbert: They'd already voted her left shoulder an honorary member. It was the only part of her that attended every rehearsal. She later ran a fibromyalgia support group. Same telephone work. Different people. They discussed posting the genetic paper to doctors. Vera said postage came out of refreshments and refused. She still sends that doctor a Christmas card. “From your favourite psychosomatic patient.” He's a rheumatologist now. The operetta society eventually moved downstairs. Vera made forty-three telephone calls to arrange it.\n\nDaniel: How do you make care acknowledge all that work without turning the patient into the person coordinating everything again?\n\nHerman: Continuity helps. One clinician keeping track of symptoms, treatment goals and what has already failed can reduce repeated explanations and disconnected prescriptions. It also makes a fluctuating condition easier to assess than a succession of isolated appointments.\n\nCorn: The point worth keeping is that biological recognition and effective treatment are separate achievements. The genetics strengthens the explanation. It hasn't supplied the relief patients need.\n\nHerman: Accepting that separation lets us reject dismissal without exaggerating what current medicines can deliver.\n\nCorn: I'd like future trials to measure whether people regain time and capacity, including the work they currently do just to keep ordinary life functioning.\n\nHerman: Thanks to Hilbert Flumingtop for producing today's episode.\n\nCorn: If you want more of this, try episode four, If Your Voice Ages, Does Your Fine-Tune Become Useless; episode sixty-two thirty-one, Why a Cold Makes Your Whole Body Ache; and episode fifty-seven, From Lawyers in Limousines to Developers in Their PJs. This has been My Weird Prompts, the human-AI collaboration podcast.\n\nHerman: If this helped clarify a condition you've mostly heard argued about, leave us a review.\n\nDaniel: Thanks for getting into it. See you soon.\n\nCorn: Until next time.","showNotes":"Fibromyalgia occupies an odd position in medicine: a condition affecting an estimated two to four percent of people worldwide, yet still without a blood test or a definitive biomarker. The science of biological susceptibility has moved much faster than the science of relief, and reading the latest genetics alongside the latest drug review makes that gap painfully clear.\n\nA July analysis in Nature Medicine compared genetic variation across roughly 2.5 million people, including about 55,000 diagnosed cases, and identified 26 associated regions of the genome. The implicated biology was enriched in brain tissues and neural cell types, directly challenging the old framing of fibromyalgia as a diagnosis of exclusion rather than a genuine biological illness. The most striking finding was a coding variant in HTT, the gene associated with Huntington's disease — carriers showed about nine percent higher odds of fibromyalgia, a small individual effect but a significant biological clue.\n\nThe condition is best understood as nociplastic pain: altered pain processing without tissue damage or nerve lesions proportionate to the symptoms. Central sensitisation explains why light touch can hurt and why pain, fatigue, unrefreshing sleep and cognitive difficulties reinforce one another. Genetic correlations above 0.7 with low back pain, PTSD and irritable bowel syndrome suggest overlapping inherited susceptibility rather than coincidental co-occurrence.\n\nImportant caveats remain. The study was roughly 90 percent European ancestry, women are diagnosed about three times as often despite nearly identical genetic architecture across sexes, and the autoimmune hypothesis is still open. Twenty-six clues are not yet a diagnostic barcode — but they are a much stronger foundation than what came before.","promptSanitized":"Hannah, Ezra and I are all down for the camp today with a very nasty stomach bug and cold. These have been coming and coming over the past few months. We did an episode earlier in which I asked why viral infections cause stomach aches. For some reason this made me think about fibromyalgia. Maybe a lesser medical mistre than the common cold, but a condition you still hear something about. I have to admit that I know very little about this, but recall reading that like CFS was for many years dismissed as a garbage diagnosis, proved to have some biological underpinning. What's the actual state of that today? What treatments are available, how many people have it, and what actually Is a thought too involved?","transcriptUrl":"https://episodes.myweirdprompts.com/transcripts/fibromyalgia-genetics-pain-science-16518.md","url":"https://myweirdprompts.com/episode/fibromyalgia-genetics-pain-science-16518/","_links":{"self":"https://myweirdprompts.com/api/episodes/fibromyalgia-genetics-pain-science-16518.json","html":"https://myweirdprompts.com/episode/fibromyalgia-genetics-pain-science-16518/","audio":"https://episodes.myweirdprompts.com/audio/fibromyalgia-genetics-pain-science-16518.m4a"}}